Evidence map›Paper›PMID 40682675›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Yizhao Xie, Yifan Chen, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shuyi Lin, Shaoli Song, Biyun Wang, Zhongyi Yang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yizhao Xie *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yifan Chen *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Cheng Liu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yannan ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Chengcheng GongDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuyi LinDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shaoli SongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. shaoli-song@163.com.
Biyun WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. wangbiyun0107@hotmail.com.
Zhongyi YangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. yangzhongyi21@163.com.ORCID 0000-0001-6195-9942

Funding

Beijing Science and Technology Innovation Medical Development Foundation KC2022-ZZ-0091-4Beijing Xisike Clinical Oncology Research Foundation Y-2022HER2AZQN-0378Beijing Xisike Clinical Oncology Research Foundation Y-Young2022-0286National Natural Science Foundation of China 82102722National Natural Science Foundation of China 82373340
6 · The paper itself

Abstract

backgroundWhile CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body PATIENTS AND

methodsWe screened all 1613 HR+/HER2- metastatic breast cancer (MBC) patients from 2020 to 2024 at Fudan University Shanghai Cancer Center. Patients who received standard first line treatment were enrolled in this retrospective study.

resultsA total of 473 patients were included in the study. 156(33.0%) and 317 (67.0%) patients were screened or unscreened by

conclusionsHR + /HER2- MBC patients with FES-guided initial treatment showed significantly better efficacy than those who had not been assessed by

Indexed as

Breast NeoplasmsEstradiolPositron Emission Tomography Computed TomographyAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm MetastasisProgression-Free SurvivalReceptors, EstrogenRetrospective Studies16-fluoroestradiolERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstradiolReceptors, Estrogen18F-fluoroestradiol positron emission tomography/computed tomographyBreast cancerCDK4/6 inhibitorsER heterogeneityMetastatic breast cancer

Identifiers

PMID40682675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.